LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

Strona główna・Stock List・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Closed

SectorHealthcare

9.61 0.42

Buy Sell

Overview

Share price change

24h

Current

Min

9.47

Max

9.81

Key metrics
By Trading Economics
Income	11M -20M
Sales	5.9M 40M
EPS	-0.19
Profit margin	-49.569
Employees	184
EBITDA	16M -19M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+148.17% upside

Market Stats
By TradingEconomics
Market Cap	234M 983M
Previous open	9.19
Previous close	9.61

News Sentiment

By Acuity

92%

6 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

6.26 / 7.47 Support & Resistance

Day One Biopharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 gru 2025, 21:41 UTC

Acquisitions, Mergers, Takeovers

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

24 gru 2025, 14:57 UTC

Acquisitions, Mergers, Takeovers

Accenture to Acquire Cabel Industry from Fibonacci Group

24 gru 2025, 12:48 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Repare Therapeutics Shares Rise on $30 Million Asset Deal With Gilead

24 gru 2025, 12:21 UTC

Major Market Movers

Nike Shares Tick Up After Apple CEO Tim Cook Buys $2.9 Million of Its Stock

24 gru 2025, 22:22 UTC

Acquisitions, Mergers, Takeovers

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 gru 2025, 21:26 UTC

Acquisitions, Mergers, Takeovers

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24 gru 2025, 19:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 gru 2025, 19:35 UTC

Market Talk

Treasury Yields Decline Ahead of Christmas -- Market Talk

24 gru 2025, 19:09 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

24 gru 2025, 19:09 UTC

Market Talk

Acquisitions, Mergers, Takeovers

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24 gru 2025, 19:06 UTC

Market Talk

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

24 gru 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Futures Give Back Some Gains -- Market Talk

24 gru 2025, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

24 gru 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 gru 2025, 17:08 UTC

Acquisitions, Mergers, Takeovers

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 gru 2025, 16:53 UTC

Acquisitions, Mergers, Takeovers

Nike Climb Boosts Dow, S&P 500 -- WSJ

24 gru 2025, 16:31 UTC

Market Talk

Acquisitions, Mergers, Takeovers

ServiceNow Gets Top-Tier Asset and Talent With Armis Buy -- Market Talk

24 gru 2025, 16:28 UTC

Acquisitions, Mergers, Takeovers

Lam Research Is at All-Time Highs. Its CEO Just Sold $27 Million Worth of Stock. -- Barrons.com

24 gru 2025, 16:17 UTC

Market Talk

Dollar Stable as U.S. Layoffs Remain at Bay -- Market Talk

24 gru 2025, 15:33 UTC

Acquisitions, Mergers, Takeovers

Nike Shares Get a Lift After Apple's Tim Cook Doubles His Personal Stake -- WSJ

24 gru 2025, 15:30 UTC

Acquisitions, Mergers, Takeovers

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 gru 2025, 15:19 UTC

Acquisitions, Mergers, Takeovers

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 gru 2025, 14:49 UTC

Acquisitions, Mergers, Takeovers

Mexico's Ollamani Sells Stake in Azteca Stadium

24 gru 2025, 14:19 UTC

Market Talk

U.S. Natural Gas Futures Move Lower After Big Jump -- Market Talk

24 gru 2025, 14:08 UTC

Acquisitions, Mergers, Takeovers

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 gru 2025, 14:06 UTC

Market Talk

Oil Futures Edge Up on Geopolitical Risk Premium -- Market Talk

24 gru 2025, 13:24 UTC

Market Talk

Canada's Economy Needs More Help Amid Dismal GDP Report -- Market Talk

24 gru 2025, 12:59 UTC

Acquisitions, Mergers, Takeovers

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 gru 2025, 12:51 UTC

Acquisitions, Mergers, Takeovers

Disney Could Be the Real Winner from the Warner Takeover Battle. Here's Why. -- Barrons.com

24 gru 2025, 12:38 UTC

Acquisitions, Mergers, Takeovers

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

Peer Comparison

Price change

Day One Biopharmaceuticals Inc Forecast

Price Target

By TipRanks

148.17% upside

12 Months Forecast

Average 23.75 USD 148.17%

High 34 USD

Low 16 USD

Based on 9 Wall Street analysts offering 12 month price targets forDay One Biopharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Day One Biopharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

6.26 / 7.47Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

6 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.